pepdex
← Back to index
№ 023

Survodutide

Boehringer Ingelheim dual agonist (GLP-1 + glucagon). Glucagon activation boosts metabolic rate, giving stronger fat-burn signal than GLP-1-only drugs.

Fat Loss
Evidence: Moderate
Half-life
~6 days
Route
Subcutaneous
Cycle
Open-ended, titrate over months
Schedule
Once weekly
In plain English

Survodutide is Boehringer Ingelheim's dual agonist (GLP-1 + glucagon) — a competitor to Retatrutide. Stronger fat-burn signal than the GLP-1-only drugs because it activates glucagon, which boosts metabolic rate. Phase 2 data is promising. Once-weekly.

Status & legality
Natty?
Not natty
FDA
Not approved

Investigational. Phase 3 trials by Boehringer Ingelheim.

Compounding
Investigational

In clinical trials, not yet approved for prescription.

WADA
Not listed
Prescribed

Not yet approved. Trial access only.

Who it's for

  • →Users plateaued on GLP-1-only drugs
  • →People targeting >15% body weight loss
  • →Phase 2 / 3 trial-followers wanting cutting-edge

What to expect

  1. Week 1

    Appetite drops. Mild nausea. Slight body-temp uptick (glucagon thermogenesis).

  2. Week 4

    First titration step. ~3-6 lb down for most users.

  3. Week 8

    Cumulative loss similar to Retatrutide trajectory.

Dosing protocol

Start 0.3 mg sub-q weekly. Titrate over 4-week steps up to 6.0 mg in trials.

Stacks well with

Standalone is the norm

Side effects

01Nausea (especially titration steps)
02Diarrhea or constipation
03Mild fatigue
04Slightly elevated heart rate (glucagon effect)

When NOT to use

  • ⚠MTC / MEN-2 history
  • ⚠Pancreatitis history
  • ⚠Pregnancy / nursing
  • ⚠Severe cardiovascular disease

Bloodwork to monitor

  • • Lipid panel
  • • ALT/AST
  • • A1C

Common mistakes

  • • Titrating too fast
  • • Treating elevated HR as 'caffeine sensitivity'
  • • Not adjusting protein during the cut

Educational only. User-specific dosing is between you and a qualified provider.

Frequently asked

What is Survodutide?+
Survodutide is Boehringer Ingelheim's dual agonist (GLP-1 + glucagon) — a competitor to Retatrutide. Stronger fat-burn signal than the GLP-1-only drugs because it activates glucagon, which boosts metabolic rate. Phase 2 data is promising. Once-weekly.
Is Survodutide FDA approved?+
Investigational. Phase 3 trials by Boehringer Ingelheim.
Is Survodutide banned by WADA?+
Survodutide is not currently on the WADA prohibited list.
Are you still natty after taking Survodutide?+
No. Survodutide is a performance-enhancing peptide and would disqualify a strict natty claim.
Do doctors prescribe Survodutide?+
Not yet approved. Trial access only.
What's the typical dose of Survodutide?+
Start 0.3 mg sub-q weekly. Titrate over 4-week steps up to 6.0 mg in trials.
What are the side effects of Survodutide?+
Common side effects include: Nausea (especially titration steps); Diarrhea or constipation; Mild fatigue; Slightly elevated heart rate (glucagon effect). Less common effects and full safety details are on the entry page.
How long until Survodutide starts working?+
Appetite drops. Mild nausea. Slight body-temp uptick (glucagon thermogenesis).